Grants and Contributions:
The primary immediate goal of the company is to introduce a family of ESR spectrometers and sub-systems to measure and control microscale spin systems interfaced with high-sensitivity superconducting quantum electronics with the goal of disrupting the protein structure measurement market and revolutionizing drug target identification in the pharmaceutical industry.
The amendment has been completed to extend the project from 2023-03-31 to 2023-09-30. This is a repayable contribution.
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.